# iMMagine-1 (NCT05396885)

> Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05396885
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Kite, A Gilead Company
- Conditions: Multiple Myeloma
- Interventions: anitocabtagene-autoleucel
- Enrollment: 136
- Primary outcome: Overall Response Rate (ORR)

## Commentary we found

- YouTube: 23
- X threads: 16
- Podcasts: 12

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=immagine-1-nct05396885

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05396885", "email": "<work email>"}; the inbox owner confirms by the emailed link.